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introduced into cancer cells, in which the gene is inactivated, to restore 
the cell’s normal gene functions. Such introduction of TSGs in the 
cancer cells generally induces apoptosis and/or cell cycle arrest. Gene 
therapy using various known and newly identiﬁed TSGs as therapeutic 
genes have reached clinical trials for treatment of several cancer types. 
However, as different types of cancers have different tumor suppressor 
deﬁciencies, the strategy must be customized to each type. Thus, the 
aim of this study is to identify and characterize novel TSG candidate(s) 
speciﬁc SCLC, which eventually can be tested for use in cancer gene 
therapy. 
By a global gene expression analysis (Affymetrix) on a large panel 
of SCLC cell lines, corresponding tumor xenografts, and transformed 
mouse cell lines, we have identiﬁed four genes, whose expression is 
markedly downregulated in cancer and transformed mouse cell lines 
compared to normal cells and tissues. This was further veriﬁed by 
semi-quantitative RT-PCR. To determine whether they posses tumor 
suppressing activity we are currently investigating the effect of overex-
pression of each of these genes on cell proliferation, migration and cell 
cycle arrest by transiently transfecting selected SCLC and transformed 
mouse cell lines. If any demonstrate tumor suppressive activity, they 
will be chosen as potential candidates for the development of gene 
therapy for patients with SCLC.
An update will be presented.
P2-155 BSTB: Tumor and Cell Biology Posters, Tue, Sept 4 
STI-571 inhibits the growth of non-small cell lung cancer cell and 
intensifies the cisplatin effect in vitro
Zhou, Caicun; Su, Chumxia; Su, Bu; Zhao, Yingmin 
Dept. Medical Oncology, Shanghai Pulmonary Hospital, Tongji Univer-
sity, Shanghai, China
Background: STI571 Gleevec, Imatinib(c) is the ﬁrst cancer -related 
signal transduction inhibitor which selectively suppresses the activity 
of c-KIT, ABL and platelet-derived growth factor receptor(PDGFR). 
Methods: We conducted MTT assay to explore the growth inhibitory 
effect of STI571 alone or with cisplatin on lung cancer cells, cell cycle 
analysis to conﬁrm the cell distribution, immunocytochemistry to test 
the expression of PDGFRs, c-KIT in the non-small cell lung cancer cell 
lines immunohistochemistry to investigate the expression of PDGFRs 
and c-KIT. 
Results: A549-resistant cell lines showed marked inhibition of cell 
growth after treatment with STI571 and combination with cisplatin,but 
not A549-sensetive cells. Cell cycle analysised by ﬂow cytometry 
revealed that STI571 treatment increased the fraction of A549-resistant 
cells in S and G2/M phases,respectively,indicating induction of S and 
G2/M transition arrest.A549 cell lines highly express PDGFRs, A549-
resistant cell lines also express c-KIT.
Conclusion: These results provide a potential therapeutic selection for 
non-small cell lung cancer. STI571 as a single agent or in combination 
with cisplatin is a potential new targeted strategy.
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Background and Objectives: Most lung cancer patients cannot be 
cured with current therapeutic modalities. Drug resistance is one of 
the major causes in treatment failure of non-small cell lung cancer 
{NSCLC). Classical drug resistant mechanisms have been elucidated 
upon monocellular models. However, these models do not consider the 
tumor microenvironment in vivo. Recently, interactions between the tu-
mor cells and extracellular matrix (ECM) have been shown to be one of 
the mechanisms of drug resistance. We investigated effects of ECM on 
cisplatin-induced apoptosis of the cell line A549 and cisplatin-resistant 
cell line A549-DDP, and the role of phosphatidylinositol 3’-kinase(PI3-
K) in ECM’s signal pathway. 
Methods: A549 and A549-DDP cells were cultured in RPMI 1640 
supplemented with 10% fetal calf serum in vitro, 6 µmol/L cisplatin 
(DDP )was added to maintain the drug resistant phenotype of the A549-
DDPcells. The inhibitory effects of DDP and/or LY294002 (PI3-K 
inhibitor) on cellular proliferation were tested by methabenzthiazuron 
(MTT) assay. Immunocytochemistry was used to detect the expression 
of extracellular matrix and integrin β1 of these two cell lines, respec-
tively. Cell adhesion experiments were used to test cell adhesion rates. 
Flow cytometry was applied to study the inﬂuence of collegen IV (C 
IV) and LY294002 on A549/DDP cells’ apoptosis and cell cycle distri-
bution before and after DDP treatment. 
Results: The expression of ECM proteins in cisplatin-sensitive and cis-
platin-resistance lung cancer cells were different. Extracellular matrix 
Cmediated cell adhesion promotes survival of A549 and A549-DDP 
cells from cisplatin insults. Pre-coating with collagen IV protect non-
small cell lung cancer cells from drug-induced growth inhibition, which 
is PI 3-kinase/Akt-dependent. Combining cisplatin with LY294002 
caused greater increases in apoptosis compared with that caused by the 
inhibitor or cisplatin alone. Collagen IV changed A549 cells cell cycle 
distribution, with an increase in G1 phase, a reduction in S and G2/M 
phases, as treated with cisplatin or combined with LY294002. After be-
ing infected with dominant-negative forms of integrin β1 plasmid, both 
of these two cell lines can become relatively sensitive to cisplatin. 
Conclusions: ECM may provide protection against cisplatin-induced 
apoptosis of A549 and A549-DDP cells, while LY294002 increases 
the growth inhibitory effect of cisplatin. Integrin &β1 signaling and 
PI3-Kinase pathway may be important survival pathways of drug-in-
duced apoptosis in lung cancer cells and activation of this pathway may 
contribute to the generation of drug resistance.
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